Featured Publications
Joint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial
Gueorguieva R, Rosenheck R, Lin H. Joint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial. Journal Of The Royal Statistical Society Series A (Statistics In Society) 2011, 175: 417-433. PMID: 22468033, PMCID: PMC3315284, DOI: 10.1111/j.1467-985x.2011.00719.x.Peer-Reviewed Original ResearchLongitudinal outcomesClinical Antipsychotic TrialsQuality of lifeSchizophrenia clinical trialsStudy medicationAntipsychotic medicationClinical trialsAntipsychotic TrialsStudy participantsPhase IIntervention effectivenessMedicationsSignificant differencesSelection biasTrialsOutcomesJoint modelling approachCauses of dropoutLarge percentageParticipantsTolerabilityPatientsOutcome valuesEffect of dropoutStudy schedule
2020
Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity
Grilo CM, White MA, Masheb RM, Ivezaj V, Morgan PT, Gueorguieva R. Randomized Controlled Trial Testing the Effectiveness of Adaptive “SMART” Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity. American Psychologist 2020, 75: 204-218. PMID: 32052995, PMCID: PMC7027689, DOI: 10.1037/amp0000534.Peer-Reviewed Original ResearchConceptsStepped-care treatmentCognitive behavioral therapyWeight loss medicationsBinge-eating disorderStepped careRemission rateWeight lossBehavioral weight lossSignificant weight lossBinge-eating frequencySignificant time effectControlled TrialsTreat analysisTreatment respondersMedicationsPlaceboMixed model analysisClinical practiceNonrespondersPatientsObesityBinge eatingCareMonthsTreatment
2007
Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam
Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcohol Clinical And Experimental Research 2007, 31: 604-611. PMID: 17374039, DOI: 10.1111/j.1530-0277.2007.00344.x.Peer-Reviewed Original ResearchConceptsAlcohol withdrawal symptomsWithdrawal symptomsActive medicationAlcohol withdrawalGlutamatergic activationEthanol detoxificationAspartate glutamate receptor antagonistGlutamate release inhibitorGlutamate receptor antagonistsMale alcohol-dependent inpatientsAdditional diazepamDiazepam administrationClinical evidenceStandard pharmacotherapyReceptor antagonistAlcohol-dependent inpatientsRelease inhibitorEthanol dependenceAlcohol abstinenceGlutamate receptorsReceptor inhibitorsWithdrawal severityPlaceboMedicationsNew treatments
2005
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder
Blumberg HP, Donegan NH, Sanislow CA, Collins S, Lacadie C, Skudlarski P, Gueorguieva R, Fulbright RK, McGlashan TH, Gore JC, Krystal JH. Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology 2005, 183: 308-313. PMID: 16249909, DOI: 10.1007/s00213-005-0156-7.Peer-Reviewed Original ResearchConceptsUnmedicated bipolar disorderMood-stabilizing medicationsBipolar disorderBD participantsPotential treatment targetMagnetic resonance imagingPreliminary evidenceMethodsFunctional magnetic resonance imagingAnterior cingulate activationResultsThe groupMedication effectsFunctional abnormalitiesHealthy comparison participantsObjectivesThe aimAnterior cingulateTreatment targetsResonance imagingMedicationsHC participantsAmygdala activationCingulate activationAmygdala increasesComparison participantsEmotional stimuliAbnormalities